tbuckley/cabot-search huggingface dataset:
Abstract 170: Temperature Maintenance and Oxygen Use in Newborns at Birth: A Surveillance of Clinical Practice and Compliance with Neonatal Resuscitation Guidelines
Authors: Georg M Schmölzer, Roxanne Pinson, Marion Molesky, Heather Chinnery, Karen Foss, Po-Yin Cheung
Journal: Circulation (2014)

Background: Guidelines of neonatal resuscitation are revised regularly. Gaps in knowledge transfer commonly occur when the guidelines are communicated to the clinical practitioners. Maintaining body temperature and supporting oxygenation are main goals that clinical practitioners aim to achieve in assisting newborns during the feto-neonatal transition at birth. Objectives: In this study, we aim to examine the compliance to guidelines in neonatal resuscitation regarding the temperature maintenance and oxygen use in newborns at birth. Methods: From October to November 2013, a prospective questionnaire surveillance was conducted in all attended deliveries at all four hospitals in Edmonton, Alberta, Canada. All clinical practitioners (registered nurses, physicians and respiratory therapists) were requested to complete the questionnaires immediately after the attended delivery regarding temperature maintenance and oxygenation monitoring. Descriptive statistics were used with mean±SD (range) and % presented. Results: During the 14-days study period, data was obtained in 518 of 712 (73%) attended deliveries of newborns with gestational age 38.6±2.0 (23-42) weeks and birth weight 3324±589 (348-6168) g. Of these deliveries, 58% were normal vaginal deliveries and 29% were cesarean sections. There were 8.8% and 8.4% newborns who required positive pressure ventilation and continuous positive pressure, respectively. Radiant warmer heat was used in 81% (419/518) with 63% (266/419) turned to full power. Room temperature was 21.6±1.6 (17-31)°C. Body temperature at 30-60 min after birth was 36.8±0.5 (32.4-38.1)°C with hypothermia (&lt;36.5°C) in 17%. Percutaneous oxygen saturation was measured in 15% newborns and 96% had sensors placed at the right wrist. At the initiation of resuscitation, 21% oxygen was used in 76% and the oxygen concentration was adjusted according to an oxygen saturation chart in 17%. In 70% of the cases, clinical practitioners commented that this chart was not helpful. Conclusions: Gaps in knowledge transfer contribute to non-compliance in the guidelines of neonatal resuscitation for temperature maintenance and oxygen use. Caution is needed to avoid hypothermia and hyperoxia in at-risk populations such as prematurity.
Association of 25-Hydroxyvitamin D and Parathyroid Hormone With Incident Hypertension
Authors: Adriana J. van Ballegooijen, Bryan Kestenbaum, Michael C. Sachs, Ian H. de Boer, David S. Siscovick, Andrew N. Hoofnagle, Joachim H. Ix, Marjolein Visser, Ingeborg A. Brouwer
Journal: Journal of the American College of Cardiology (2014)
SURGICAL TREATMENT OF BRONCHIECTASIS
Authors: E B KAY, R H MEADE, F A HUGHES
Journal: Annals of Internal Medicine (1947)

ExcerptPermanent cure of bronchiectasis can be obtained only by pulmonary resection. The operative mortality and morbidity are today so small in contrast to that inherent in the disease that operation can be recommended without hesitation. The opinions in this report are based on the treatment of 390 patients with bronchiectasis at this Chest Center and at Percy Jones General Hospital during the past three years. During this period there have been 220 consecutive lobectomies with only one death, an incidence of 0.4 per cent. This fatality was the fourth patient to be operated upon at this hospital. One hundred and...
Abortion Ban Trial
Authors: Brian Vastag
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Back Pain Study
Authors: Joan Stephenson
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
128. Use of Chimeric Adenoviral Vectors To Assess Capsid Neutralization Determinants
Authors: Laura Denby, Delyth Graham, Dan J. Von Seggern, Stuart A. Nicklin, Andrew H. Baker
Journal: Molecular Therapy (2004)

In order to target vascular tissues site-specifically in vivo following systemic delivery it is necessary to develop platform vectors that possess negligible hepatic tropism. For Adenoviruses (Ad) this can be achieved by capsid mutation, capsid modification or pseudotyping which exploits Ad diversity. There are 51 known human Ads, divided into subgroups A–F. Certain Ads belonging to subgroup B and D bind to CD46 (Gagger, 2003; Wu, 2004) but other Ads bind receptors other than CD46 or the previously identified coxsackie and adenovirus receptor (CAR) and may therefore show a more favourable infectivity profile. Using pseudotyping we have investigated the infectivity and biodistribution of candidate fibers from subgroups B, C and D for vascular cell and hepatocyte transduction in vitro and their tissue distribution in vivo following iv administration. In vitro evaluation revealed that the subgroup D vectors Ad5/19p and Ad5/37 did not support the transduction of HepG2 hepatocytes (Ad5/19p 0.22% ± 0.06% vs Ad5; Ad5/37 1.5% ± 0.2% vs Ad5) whereas the other vectors evaluated, Ad5/3 and Ad5/16 produced high levels of transduction (Ad5/3 113% ± 10% vs Ad5; Ad5/16 74% ± 6% vs Ad5). The lack of hepatic tropism of Ad5/19p and Ad5/37 was replicated in both rat and mouse hepatocytes (ARL-6 and CCL-2254). Infectivity studies on vascular cells showed that Ad5/19p and Ad5/37 could achieve similar or improved transduction compared to Ad5 [Human saphenous vein endothelial cells (HSVEC) Ad5/19p and Ad5/37 produced 87% ± 11% and 84% ± 8% respectively of Ad5 transduction]. Both subgroup D vectors produced an increased transduction of human saphenous vein smooth muscle cells when compared to Ad5 (Ad5/19p 248% ± 42, Ad5/37 502% ± 130% vs Ad5 transduction). Transduction was mediated through a CAR independent pathway for Ad5/19p and Ad5/37 since an anti CAR neutralizing antibody failed to inhibit infection. We also examined CD46 as a possible primary receptor for Ad5/19p and Ad5/37. We found that Ad5/19p could not transduce CHO cells expressing the BC1 isoform of CD46 but Ad5/37 did albeit at much lower levels than Ad5/16. In vivo studies with Ad5/19p and Ad5/37 vectors were performed by iv injection into 12 week old male WKY rats. Animals were sacrificed at 1 hour and both Ad5/19p and Ad5/37 showed a 45% reduction (p < 0.05) in virion liver accumulation compared to Ad5, assessed by realtime PCR. At 5 days post viral infusion only Ad5 DNA was detectable in the liver. Transgene expression in liver sections was significantly reduced for Ad5/19p and Ad5/37 compared to Ad5 (Ad5 95%, Ad5/19p 12% and Ad5/37 7%, p < 0.05).These findings indicate that Ad19p and Ad37 pseudotyped Ad5 vectors show reduced hepatocyte transduction in vitro and in vivo and are promising for the development of systemically-injectable vascular-targeted gene therapies.
Delayed-Enhanced Magnetic Resonance Imaging in Nonischemic Cardiomyopathy
Authors: Frank M. Bogun, Benoit Desjardins, Eric Good, Sanjaya Gupta, Thomas Crawford, Hakan Oral, Matthew Ebinger, Frank Pelosi, Aman Chugh, Krit Jongnarangsin, Fred Morady
Journal: Journal of the American College of Cardiology (2009)
Abstract P072: Low-Carbohydrate-Diets and Cardiovascular and Total Mortality in Japanese. A 29-year Follow-up of NIPPON DATA80
Authors: Yasuyuki Nakamura, Nagako Okuda, Tomonori Okamura, Aya Kadota, Naoko Miyagawa, Takehito Hayakawa, Yoshikuni Kita, Akira Fujiyoshi, Masato Nagai, Naoyuki Takashima, Takayoshi Ohkubo, Katsuyuki Miura, Akira Okayama, Hirotsugu Ueshima
Journal: Circulation (2014)

Background: Long-term safety of low-carbohydrate-diets in Asian populations, whose carbohydrate intake is relatively high, is not known. Methods: We examined the association of low-carbohydrate-diets with CVD and total mortality using the National Integrated Project for Prospective Observation of Noncommunicable Disease and Its Trends in the Aged, (NIPPON DATA80) database with a 29-year follow-up. At the baseline in 1980, data were collected on study participants ages≥30 years from randomly selected areas in Japan. We calculated low-carbohydrate-diet scores based on the percentage of energy as carbohydrate, fat, and protein, estimated by 3-day weighed food records. We followed 9,200 participants (56% women, mean age 51 y). Results: During the follow-up, there were 1,171 CVD deaths (52% in women), and 3,443 total deaths (48% in women). The multivariate-adjusted hazard ratio (HR) for CVD mortality using the Cox model comparing highest versus lowest deciles for a low-carbohydrate-diet score was 0.59 (95% confidence interval [CI], 0.38-0.92, trend P=0.019) for women; 0.74 (95% CI: 0.55-0.99, trend P=0.033) for women and men combined; HR for total mortality was 0.73 (95% CI: 0.57-0.93, trend P=0.020) for women; 0.84 (95% CI: 0.72-0.99, trend P=0.030) for women and men combined. None of the associations in men alone were statistically significant. We did not note any differential effects between animal and plant based low-carbohydrate-diets. Conclusions: Moderate diets lower in carbohydrate and higher in protein and fat were significantly inversely associated with CVD and total mortality in women, and women and men combined.
Abstract 81: Effect of HSP90 inhibition on the gene expression profile of MDM2 transfected LNCaP-MST prostate cancer cells
Authors: Thiagarajan Venkatesan, Ali Alaseem, Khalid Alhazzani, Appu Rathinavelu
Journal: Cancer Research (2015)

Abstract The heat shock protein 90 (HSP90) is a major molecular chaperone of the cell that appears to be a master regulator of the stability and activity of multiple oncoproteins such as HER2, Akt, Bcr-Abl, c-Kit, EGFR and BRAF. Recent approaches have revealed that most of the target proteins of HSP90 are protein kinases or transcription factors which play important roles in the cellular carcinogenesis. The HSP90 also plays an important role in the regulation of cell cycle, proliferation, vascularization, invasion and metastasis of cancer cells, as well as in maintaining the stability and functions of several carcinogenic proteins involved in altering the signal transduction pathways of apoptosis. The 17-allylamino-17-demethoxygeldanamycin (17-AAG) is a well known inhibitor of HSP90 and it was speculated that, this inhibitor may have particular value in the antitumor and angiostatic therapies. Hence, we were trying to determine the expression profile of the genes in the angiogenesis pathway following treatment of MDM2 overexpressing LNCaP-MST prostate cancer cells with 17-AAG. In the LNCaP-MST cells, the expression of genes such as TNF-α, MMP9 and TGFB1 were found to be significantly up-regulated compared to the LNCaP cells. Hence, MDM2 overexpression was suspected as the primary cause of these increases. However, after treating the LNCaP-MST cells with 10 μm 17-AAG for 24 hrs, several of these genes were significantly altered compared to the untreated LNCaP-MST cells. In particular, the 17-AAG treatment significantly down-regulated the expression of TNF-α, TGFB1, ID1, IL8 and F3 which are involved in the regulation of angiogenesis and tumor growth. The heat map and scatterplot analysis clearly confirmed the alterations in the expression levels of these genes following 17-AAG treatment. Cluster analysis further indicated that the gene expression patterns are positively correlated with the anti-angiogenic effects of 17-AAG treatment in LNCaP-MST cells compared to untreated cells. Our results offer convincing evidence to suggest that the inhibition of HSP90 can control both pro-angiogenic and cell proliferative signals in LNCaP-MST cells. (The financial support from the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida is gratefully acknowledged). Citation Format: Thiagarajan Venkatesan, Ali Alaseem, Khalid Alhazzani, Appu Rathinavelu. Effect of HSP90 inhibition on the gene expression profile of MDM2 transfected LNCaP-MST prostate cancer cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 81. doi:10.1158/1538-7445.AM2015-81
Endogenous Sex Hormones and Cardiovascular Disease Incidence in Men
Authors: Johan Ärnlöv, Michael J. Pencina, Shreyasee Amin, Byung-Ho Nam, Emelia J. Benjamin, Joanne M. Murabito, Thomas J. Wang, Philip E. Knapp, Ralph B. D'Agostino, Shalendar Bhasin, Ramachandran S. Vasan
Journal: Annals of Internal Medicine (2006)

Background: Data suggest that endogenous sex hormones (testosterone, dehydroepiandrosterone sulfate [DHEA-S], and estradiol) influence cardiovascular disease (CVD) risk factors and vascular function. Yet, prospective studies relating sex hormones to CVD incidence in men have yielded inconsistent results. Objective: To examine the association of circulating sex hormone levels and CVD risk in men. Design: Prospective cohort study. Setting: Community-based study in Framingham, Massachusetts. Participants: 2084 middle-aged white men without CVD at baseline. Measurements: The authors used multivariable Cox regression to relate baseline levels of testosterone, DHEA-S, and estradiol to the incidence of CVD (coronary, cerebrovascular, or peripheral vascular disease or heart failure) during 10 years of follow-up. Results: During follow-up, 386 men (18.5%) experienced a first CVD event. After adjustment for baseline standard CVD risk factors, higher estradiol level was associated with lower risk for CVD (hazard ratio per SD increment in log estradiol, 0.90 [95% CI, 0.82 to 0.99]; P = 0.035). The authors observed effect modification by age: Higher estradiol levels were associated with lower CVD risk in older (median age >56 years) men (hazard ratio per SD increment, 0.86 [CI, 0.78 to 0.96]; P = 0.005) but not in younger (median age ≤56 years) men (hazard ratio per SD increment, 1.11 [CI, 0.89 to 1.38]; P = 0.36). The association of higher estradiol level with lower CVD incidence remained robust in time-dependent Cox models (updating standard CVD risk factors during follow-up). Serum testosterone and DHEA-S levels were not statistically significantly associated with incident CVD. Limitations: Sex hormone levels were measured only at baseline, and the findings may not be generalizable to women and nonwhite people. Conclusions: In the community-based sample, a higher serum estradiol level was associated with lower risk for CVD events in older men. The findings are consistent with the hypothesis that endogenous estrogen has vasculoprotective influences in men.
Bill Takes Aim at Nationwide Shortage of Nurses
Authors: Rita Rubin
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Primary cutaneous follicle centre cell lymphoma of the scalp presenting with scarring alopecia
Authors: J. Kluk, R. Charles-Holmes, R.A. Carr
Journal: British Journal of Dermatology (2011)

Funding sources: none. Conflicts of interest: none declared. Madam, The World Health Organization–European Organization for Research and Treatment of Cancer distinguishes three main types of primary cutaneous B‐cell lymphoma. These are primary cutaneous follicle centre cell lymphoma (PCFCCL), marginal zone lymphoma and diffuse large B‐cell lymphoma.1 PCFCCL is the most common subtype, representing 11% of all primary cutaneous lymphomas.2 It is an indolent lymphoma, typically manifesting as solitary or grouped papules, nodules or tumours on the head, neck or upper back. Histologically, the disease is characterized by a bottom‐heavy dermal infiltrate showing irregular follicular structures with a reduced or absent mantle zone.3 Lesions generally increase in size and number over a period of years and, left untreated, may eventually progress to ulceration and scarring.4, 5 Alopecia is not a recognized presenting feature of PCFCCL. A 55‐year‐old woman presented to the department of dermatology with a 5‐year history of hair thinning, predominantly over the frontal scalp. For 3 years, the hair loss had been associated with redness, soreness and pruritus. Symptoms were limited to the scalp and the patient was systemically well. She denied photosensitivity, weight loss, pyrexia and malaise, but admitted occasional nondrenching night sweats.
Abstract 2836: Development of a companion diagnostic IHC assay for the biomarker-driven selection of C4.4a positive patients
Authors: Claudia Schneider, Joseph Couto, Yifei Zhu, Zhiming Liao, Robert Pytela, Alton Hiscox, Sabine Wittemer-Rump, Ulf Forssmann, Lars Linden, Joerg Willuda, Daniel Forler, Matthew Nelson, Ricarda Finnern, Thomas Krahn, Khusru Asadullah
Journal: Cancer Research (2014)

Abstract C4.4a (LYPD3), a GPI-anchored cell surface protein, has been identified previously as a cancer- and metastasis-associated cell surface protein. It is expressed in a variety of cancer indications and, particularly, in the squamous cell subtype of non-small cell lung cancer (NSCLC) and head and neck cancer. Targeting C4.4a with a specific antibody-drug conjugate showed a potent and selective antitumor activity in various human xenograft models and in patient-derived NSCLC tumor models (Willuda J et al., AACR 2014). Since it has been previously shown in vivo that the expression of C4.4a is required for the response to anti-C4.4a treatment, we initiated the development of an IHC assay that might be used to detect C4.4a expression in patient tumor samples. For the development of this companion diagnostic IHC assay, a novel monoclonal rabbit anti-C4.4a antibody was generated. Since C4.4a is post-transcriptionally modified by shedding, we aimed to identify an antibody that binds to a similar epitope as the therapeutic C4.4a antibody. The immunizations of rabbits with specific peptide sequences of C4.4a and with the full length C4.4a recombinant protein produced several antibody candidates. Those antibody candidates were characterized in regard to their staining characteristics, domain binding, and specificity for C4.4a. Furthermore, the staining pattern of the antibody candidates and the therapeutic C4.4a antibody were compared side by side to ensure that stainings using the newly generated antibodies are predictive for anti-C4.4a treatment. The most promising antibodies were selected to set up and optimize an IHC assay on the Ventana staining platform. In summary, we developed a companion diagnostic IHC assay that might be used to detect C4.4a expression in patient tumor samples. Citation Format: Claudia Schneider, Joseph Couto, Yifei Zhu, Zhiming Liao, Robert Pytela, Alton Hiscox, Sabine Wittemer-Rump, Ulf Forssmann, Lars Linden, Joerg Willuda, Daniel Forler, Matthew Nelson, Ricarda Finnern, Thomas Krahn, Khusru Asadullah. Development of a companion diagnostic IHC assay for the biomarker-driven selection of C4.4a positive patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2836. doi:10.1158/1538-7445.AM2014-2836